Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases

Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1243-5. doi: 10.1097/00042737-200511000-00015.

Abstract

We report two patients who developed an inflammatory bowel disease (IBD) shortly after beginning combined alpha-interferon and ribavirin treatment for HCV-related chronic hepatitis. The previous clinical history was negative for IBD in both patients, who developed diarrhoea and rectal bleeding 10 days and 6 months, respectively, after the initiation of therapy. The history, therapeutic management and the possible causal relationships of these cases are discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Drug Therapy, Combination
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Inflammatory Bowel Diseases / chemically induced*
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Ribavirin / adverse effects*
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Ribavirin